Ep. 6 - B-cells vs. Complement in IgAN: A Look at the Data from Kidney Week 2024 (with Dr. Vlado Perkovic)
Biotech Matters
sits down with Vlado Perkovic, MBBS, PhD, to discuss the IgA nephropathy trial data presented at Kidney Week 2024 in San Diego. Jeff begins by asking Dr. Perkovic to talk about why targeting B-cells is an attractive target, and why BAFF/APRIL might prove more promising than CD20. The two then discuss the data with two agents in development for the treatment of IgAN, atacicept (targeting BAFF/APRIL) and sibeprenlimab (targeting APRIL only). The conversation then pivots to the prospect of complement inhibition with FABHALTA® (iptacopan) in IgA nephropathy, including a comparison of the...
info_outline
Ep. 5 - It’s ASN Kidney Week 2024! Here’s What We’re Excited About (with Dr. Beatrice Goilav)
Biotech Matters
welcomes back returning guest nephrologist Beatrice Goilav, MD, to discuss the program featured at Kidney Week 2024 in San Diego. Dr. Goilav reflects on what has happened in the field since last year’s Kidney Week conference, as well as her hopes for what will be presented at a variety of sessions, including more data in IgA nephropathy, lupus nephritis, and FSGS. She also offers her perspective on the newest advancements with complement inhibitors in glomerular diseases – including approval of FABHALTA® (iptacopan) in IgA nephropathy – as well as recommendations for educational...
info_outline
Ep. 4 - ADC Alchemy: A Post-ASCO Discussion
Biotech Matters
Bluestar Managing Director is back from the ASCO conference in Chicago and joins Principal on the podcast again, this time to talk about all things antibody drug conjugates (ADCs) in oncology. Given the number and value of deals in this space over the past couple of years, as well as the 170+ ADCs now in clinical development, Jeff asks Erin to take stock of what we’ve learned about the potential of these molecules, with all their moving parts, and opine on what lies ahead. Over the course of this brief conversation, Erin and Jeff touch on some key questions about ADCs, including: •...
info_outline
Ep.3 What We’re Watching at ASCO 2024
Biotech Matters
As the Bluestar team prepares to head to ASCO 2024 this upcoming weekend, Bluestar Principal Jeff Fineberg sits down with Bluestar Managing Director Erin Olsen to talk about interesting abstracts related to two topics: What are the unmet needs in 1L therapy? The KRAS G12C mutation landscape
info_outline
Ep. 2 - Making Sense of the Latest IgAN Trials (with Dr. Pietro Canetta)
Biotech Matters
After attending ASN Kidney Week, Bluestar Principal Jeff Fineberg sits down with Dr. Pietro Canetta to talk all things IgA nephropathy (IgAN). After Dr. Canetta provides a brief summary of his IgAN lecture at Kidney Week, Emerging Therapeutic Options in IgA Nephropathy, the two discuss the Filspari (sparsentan) data presented from both the PROTECT study, in IgAN, the DUPLEX study, in FSGS. From there, Dr. Canetta opines on the value of surrogate endpoints in predicting the three D’s of CKD: death, dialysis, and doubling of serum creatinine (SCr). Dr. Canetta briefly discusses...
info_outline
Ep. 1 - What We’re Looking for at ASN Kidney Week 2023: A Conversation with Dr. Beatrice Goilav
Biotech Matters
In the first ever Biotech Matters podcast episode, Principal Jeff Fineberg, PhD, sits down with nephrologist Beatrice Goilav, MD, to talk all things Kidney Week. Dr. Goilav offers her thoughts on an ideal day-by-day itinerary, as well as her hopes for what will be presented at a variety of sessions, including drug trials in IgAN, and new studies of SGLT2 inhibitors. She also offers her perspective on the potential for complement inhibitors in glomerular diseases, and which of these drugs in development she is most interested in. Finally, she makes some recommendations on poster abstracts to...
info_outlineBluestar Managing Director Erin Olsen is back from the ASCO conference in Chicago and joins Principal Jeff Fineberg on the podcast again, this time to talk about all things antibody drug conjugates (ADCs) in oncology.
Given the number and value of deals in this space over the past couple of years, as well as the 170+ ADCs now in clinical development, Jeff asks Erin to take stock of what we’ve learned about the potential of these molecules, with all their moving parts, and opine on what lies ahead.
Over the course of this brief conversation, Erin and Jeff touch on some key questions about ADCs, including:
• Are ADCs living up to their promise? (1:48)
• What are some lessons learned from Enhertu? (3:20)
• What have we learned about TOP1 payloads and TROP2 targeting? (6:10)
• Have ADCs delivered on better safety than chemo? (8:40)
• What’s next for ADCs? (10:50)
Bluestar BioAdvisors LLC is a boutique consulting firm comprised of strategic experts in the business of life sciences. We help clients answer key strategic questions about asset value, positioning, and future market potential, serving as an independent, objective advisor through the critical decision-making points of portfolio planning and business development.
For more information about us, please visit Bluestar BioAdvisors’ website, Erin’s bio, and Jeff’s bio.